Reported Earnings • May 12
First quarter 2026 earnings: EPS in line with expectations, revenues disappoint First quarter 2026 results: kr0.015 loss per share (improved from kr0.036 loss in 1Q 2025). Revenue: kr27.4m (down 23% from 1Q 2025). Net loss: kr1.66m (loss narrowed 53% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 24
OrganoClick AB (publ), Annual General Meeting, May 26, 2026 OrganoClick AB (publ), Annual General Meeting, May 26, 2026, at 16:00 W. Europe Standard Time. Location: organoclick`s head office at linjalvagen 9 in taby, Sweden Reported Earnings • Feb 15
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: kr0.36 loss per share (further deteriorated from kr0.18 loss in FY 2024). Revenue: kr106.2m (down 17% from FY 2024). Net loss: kr36.4m (loss widened 102% from FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 1.1% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Major Estimate Revision • Jan 23
Consensus EPS estimates fall by 21% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -kr0.24 to -kr0.29 per share. Revenue forecast unchanged at kr110.0m. Chemicals industry in Sweden expected to see average net income growth of 27% next year. Consensus price target of kr2.00 unchanged from last update. Share price fell 5.4% to kr1.66 over the past week. Breakeven Date Change • Jan 22
Forecast breakeven date pushed back to 2028 The analyst covering OrganoClick previously expected the company to break even in 2027. New forecast suggests the company will make a profit of kr4.00m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule. Reported Earnings • Nov 06
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: kr0.08 loss per share (further deteriorated from kr0.047 loss in 3Q 2024). Revenue: kr22.5m (down 22% from 3Q 2024). Net loss: kr8.08m (loss widened 75% from 3Q 2024). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.4% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. New Risk • Nov 05
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr23m Forecast net loss in 2 years: kr4.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr4.0m net loss in 2 years). Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (kr195.8m market cap, or US$20.4m). Recent Insider Transactions • Aug 17
Independent Director recently bought kr105k worth of stock On the 14th of August, Chatarina Schneider bought around 60k shares on-market at roughly kr1.76 per share. This transaction amounted to 81% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.3m more in shares than they have sold in the last 12 months. Board Change • Aug 14
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Johan Magnusson was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 20
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: kr0.065 loss per share (further deteriorated from kr0.029 loss in 2Q 2024). Revenue: kr30.0m (down 23% from 2Q 2024). Net loss: kr6.37m (loss widened 124% from 2Q 2024). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 200%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Breakeven Date Change • Jul 18 The analyst covering OrganoClick previously expected the company to break even in 2027. New forecast suggests losses will reduce by 53% per year to 2026. The company is expected to make a profit of kr3.20m in 2027. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
Tillkännagivande • Jul 18
OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million. OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 11,543,290
Price\Range: SEK 1.76
Transaction Features: Rights Offering Major Estimate Revision • Jul 10
Consensus EPS estimates fall by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr135.0m to kr130.0m. Losses expected to increase from kr0.14 per share to kr0.16. Chemicals industry in Sweden expected to see average net income growth of 37% next year. Consensus price target of kr2.50 unchanged from last update. Share price rose 7.5% to kr2.15 over the past week. Tillkännagivande • May 20
OrganoClick AB (publ) Approves Board Changes OrganoClick AB (publ) announced at the AGM held on May 20, 2025, approved Johan Magnusson was elected as Chairman of the Board. The Board also gave a big thank to the outgoing Chairman of the board Jan Johansson for his contribution to the board and the company during his 9 years as Chairman of the board. Recent Insider Transactions • May 15
Independent Director recently bought kr129k worth of stock On the 8th of May, Johan Magnusson bought around 60k shares on-market at roughly kr2.15 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger purchase from another insider worth kr1.0m. Insiders have collectively bought kr1.2m more in shares than they have sold in the last 12 months. Major Estimate Revision • May 13
Consensus EPS estimates fall by 40% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr140.0m to kr135.0m. Losses expected to increase from kr0.10 per share to kr0.14. Chemicals industry in Sweden expected to see average net income growth of 41% next year. Consensus price target of kr2.50 unchanged from last update. Share price fell 11% to kr2.05 over the past week. New Risk • May 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr5.5m free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$100m (kr260.0m market cap, or US$26.9m). New Risk • May 04
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr5.5m free cash flow). Minor Risk Market cap is less than US$100m (kr245.3m market cap, or US$25.4m). Major Estimate Revision • Apr 30
Consensus EPS estimates fall by 67% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr143.0m to kr140.0m. Losses expected to increase from kr0.06 per share to kr0.10. Chemicals industry in Sweden expected to see average net income growth of 38% next year. Consensus price target of kr2.50 unchanged from last update. Share price fell 3.3% to kr2.34 over the past week. Tillkännagivande • Apr 16
OrganoClick AB (publ), Annual General Meeting, May 20, 2025 OrganoClick AB (publ), Annual General Meeting, May 20, 2025, at 13:00 W. Europe Standard Time. Location: at convendum, brahegatan 10, stockholm Sweden Reported Earnings • Apr 09
Full year 2024 earnings: EPS in line with expectations, revenues disappoint Full year 2024 results: kr0.18 loss per share (further deteriorated from kr0.16 loss in FY 2023). Revenue: kr127.2m (down 13% from FY 2023). Net loss: kr18.0m (loss widened 14% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Feb 27
Director recently bought kr1.0m worth of stock On the 25th of February, Charlotte Jansdotter Karlberg bought around 400k shares on-market at roughly kr2.50 per share. This transaction increased Charlotte Jansdotter's direct individual holding by 5x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.0m more in shares than they have sold in the last 12 months. Reported Earnings • Feb 15
Full year 2024 earnings: EPS in line with expectations, revenues disappoint Full year 2024 results: kr0.18 loss per share (further deteriorated from kr0.16 loss in FY 2023). Revenue: kr127.2m (down 13% from FY 2023). Net loss: kr18.0m (loss widened 14% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Feb 13
New major risk - Revenue and earnings growth Earnings have declined by 1.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.4% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr4.5m). Market cap is less than US$100m (kr263.0m market cap, or US$24.2m). Tillkännagivande • Feb 13
OrganoClick AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025 OrganoClick AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 03, 2025 Reported Earnings • Nov 07
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: kr0.047 loss per share (further deteriorated from kr0.042 loss in 3Q 2023). Revenue: kr28.9m (down 14% from 3Q 2023). Net loss: kr4.62m (loss widened 12% from 3Q 2023). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 150%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. New Risk • Nov 06
New major risk - Revenue and earnings growth Earnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr284.5m market cap, or US$26.2m). New Risk • Oct 29
New major risk - Revenue and earnings growth Earnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr288.5m market cap, or US$27.0m). Breakeven Date Change • Jul 22
Forecast to breakeven in 2025 The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr6.00m in 2025. Average annual earnings growth of 109% is required to achieve expected profit on schedule. Reported Earnings • Jul 22
Second quarter 2024 earnings released: kr0.029 loss per share (vs kr0.027 loss in 2Q 2023) Second quarter 2024 results: kr0.029 loss per share (further deteriorated from kr0.027 loss in 2Q 2023). Revenue: kr38.7m (down 5.6% from 2Q 2023). Net loss: kr2.85m (loss widened 6.6% from 2Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Major Estimate Revision • Jul 07
Consensus EPS estimates fall by 17% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr158.0m to kr155.0m. Losses expected to increase from kr0.06 per share to kr0.07. Chemicals industry in Sweden expected to see average net income growth of 33% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.78 over the past week. Tillkännagivande • Jun 15
OrganoClick AB (publ) Announces CFO Changes OrganoClick AB (publ) has appointed Carin Eklund as the new CFO for the group. She will lead OrganoClick's finance and economics department and be part of the group's management team. Carin has more than 20 years of experience from various finance functions from, among others, Bristol Myers Squibb group, ByggFakta group and Team Olivia group. Carin has a M. Sc. in Economics with a specialization in financial mathematics at Karlstad University. For more than 25 years, Carin has worked in finance departments at both manufacturing companies and service companies, in both smaller companies and large groups. Previous experiences include roles as CFO for Olivia Hemomsorg, Finance manager for the medical technology company Convatec (part of the Bristol Myers Squibb Group), Head of Business Control Nordic region at ByggFakta Group and as Strategic Controller at the kitchen manufacturer Nobia. Carin takes over as CFO on July 15, and as previously announced, OrganoClick's current CFO Jessica Sundborg will leave the company 21 of August. Tillkännagivande • May 16
OrganoClick AB (publ) Approves Board Changes OrganoClick AB (publ) at its Annual General Meeting held on 15 May 2024 approved the election of Johan Magnusson as board member. The Board also gave a big thank to the outgoing board member Malin Bugge for her contribution to the board and the company during her 4 years as a board member. Reported Earnings • May 02
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint First quarter 2024 results: kr0.022 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr38.2m (down 12% from 1Q 2023). Net loss: kr2.11m (loss widened 112% from 1Q 2023). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Major Estimate Revision • May 01
Consensus EPS estimates upgraded to kr0.06 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from kr166.0m to kr158.0m. 2024 losses expected to reduce from -kr0.09 to -kr0.06 per share. Chemicals industry in Sweden expected to see average net income growth of 48% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.24 over the past week. New Risk • Apr 30
New major risk - Revenue and earnings growth Earnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr298.7m market cap, or US$27.3m). Tillkännagivande • Apr 23
OrganoWood AB (publ) Announces Three-Year Results from the Field Study EN 12037 for Organowood Nowa Organowood Nowa is currently subjected to one of the toughest standard field tests available for wood above ground, EN 12037! The test runs for 5 years in Malaysia and Denmark and now publish the three-year results. The independent external institute Dansk Teknologisk Institut therefore carries out the EN 12037 field test with Organowood Nowa in both Denmark and Malaysia. The references, which consist of untreated pine wood and the wood impregnated with CCA (chromium, copper and arenic), which has been banned for 20 years, were also included in the test. The scale for assessing degradation ranges from grade 0-4, where 0 meas that the wood is unaffected and 4 means that the wood is completely degraded. The untreated reference in Malaysia was completely degraded after 3 years, by rot fungus but also in some cases by termites. Pine pressure-impregnated with CCA was, as expected, unaffected. But also OrganoWood Nowa was completely unaffected with grade 0 on the scale! The result shows a very good wood protection even in the warm and humid environment that a rainforest offers. The field study will continue and will continuously report results from both Denmark and Malaysia. Tillkännagivande • Apr 19
Jessica Sundborg to Leave as CFO of OrganoClick AB (publ) OrganoClick AB (publ) announced that its CFO since 2013, Jessica Sundborg is leaving her position to move on to a new position outside the company. Jessica will remain as CFO until she leaves her position after the summer. The work to recruit a successor has begun. New Risk • Apr 17
New major risk - Revenue and earnings growth Earnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr308.5m market cap, or US$28.2m). Tillkännagivande • Apr 11
Organoclick AB (Publ) Announces That Malin Bugge, Board Member, Has Declined Re-Election OrganoClick AB (publ) announced that Malin Bugge, who has been a board member since 2020, has declined re-election. Reported Earnings • Apr 09
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Mar 23
OrganoClick and PulPac Launches Plastic-Free Coffee Lid Reducing Co2 Footprint with 80% OrganoClick and PulPac has collaborated for several years in developing 100% biobased and biodegradable dry-molded products. By combining PulPac's dry molded fiber technology with OrganoClick's biobased and biodegradable binders, a biobased high-performing coffee lid, compliant with paper recycling have been developed. The innovative coffee lid is now launched for the take away market. PulPac's technology in combination with OrganoClick's biobased binders sets a new standard for high performing and sustainable packaging. It requires less energy and water than the traditional method, resulting in a reduced carbon footprint with up to 80% compared to traditional alternatives. One of the first products out is a plastic-free coffee lid which align with the recent EU legislation for take away product. Annual global consumption of coffee lids is estimated at 100,000,000,000 and with the new coffee lid, the CO2 footprint is reduced with up to 80%. The coffee lid is made green inside with the support of OrganoClick's biobased, biodegradable and home compostable binder, in part manufactured from waste streams from the food industry. The use of OrganoClick's binder resulting in a paper lid with much higher performance. The objectives are also to replace as much as possible of traditional plastic lids available on the market, thereby reducing the risk for microplastics ending up in the environment. Major Estimate Revision • Feb 22
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr183.0m to kr170.0m. Losses expected to increase from kr0.08 per share to kr0.09. Chemicals industry in Sweden expected to see average net income growth of 42% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.16 over the past week. Reported Earnings • Feb 16
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. New Risk • Jan 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr13m). Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (kr297.8m market cap, or US$28.5m). Major Estimate Revision • Jan 19
Consensus EPS estimates upgraded to kr0.14 loss The consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -kr0.17 to -kr0.14 per share. Revenue forecast steady at kr148.0m. Chemicals industry in Sweden expected to see average net income growth of 1.1% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.18 over the past week. Tillkännagivande • Dec 20
OrganoClick AB (publ), Annual General Meeting, May 15, 2024 OrganoClick AB (publ), Annual General Meeting, May 15, 2024. Recent Insider Transactions • Nov 16
Co-founder & CEO recently bought kr202k worth of stock On the 13th of November, Marten Hellberg bought around 56k shares on-market at roughly kr3.63 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Marten has been a buyer over the last 12 months, purchasing a net total of kr211k worth in shares. New Risk • Nov 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr13m). Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (kr372.2m market cap, or US$34.3m). Reported Earnings • Nov 10
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: kr0.042 loss per share (improved from kr0.093 loss in 3Q 2022). Revenue: kr33.4m (up 50% from 3Q 2022). Net loss: kr4.13m (loss narrowed 55% from 3Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 33%. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. New Risk • Nov 09
New major risk - Revenue and earnings growth Earnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Market cap is less than US$100m (kr307.6m market cap, or US$28.3m). New Risk • Nov 03
New major risk - Revenue and earnings growth Earnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Market cap is less than US$100m (kr330.1m market cap, or US$30.3m). Breakeven Date Change • Nov 03
Forecast to breakeven in 2025 The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr7.90m in 2025. Average annual earnings growth of 107% is required to achieve expected profit on schedule. Tillkännagivande • Oct 17
OrganoClick AB (publ) Announces Nomination Committee OrganoClick AB (publ) announced composition of nomination committee. It is composed of Peter Lindell, representing Cidro Förvaltning and himself, Håkan Gustavson representing Beijer Ventures, the Beijer foundations, and himself, and Mårten Hellberg, representing M. Hellberg AB and himself. Peter Lindell was appointed as Chairman of the Nomination committee as the individually largest shareholder in OrganoClick AB. Recent Insider Transactions • Aug 24
Chairman recently bought kr147k worth of stock On the 18th of August, Jan Johansson bought around 35k shares on-market at roughly kr4.20 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jan has been a buyer over the last 12 months, purchasing a net total of kr352k worth in shares. Reported Earnings • Aug 18
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: kr0.03 loss per share (improved from kr0.09 loss in 2Q 2022). Revenue: kr41.0m (up 6.5% from 2Q 2022). Net loss: kr2.67m (loss narrowed 70% from 2Q 2022). Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) exceeded analyst estimates by 25%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 13% per year. New Risk • Jul 19
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr40m Forecast net loss in 2 years: kr1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr31m). Currently unprofitable and not forecast to become profitable over next 2 years (kr1.4m net loss in 2 years). Market cap is less than US$100m (kr471.1m market cap, or US$45.8m). Major Estimate Revision • Jul 19
Consensus EPS estimates fall by 25% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr166.5m to kr152.6m. Losses expected to increase from kr0.12 per share to kr0.15. Chemicals industry in Sweden expected to see average net income decline 1.4% next year. Consensus price target of kr9.00 unchanged from last update. Share price fell 4.7% to kr4.66 over the past week. Tillkännagivande • Jun 01
Organoclick Launches Biobased and Eco-Labelled Textile Waterproofing After several years of research and development, OrganoClick is launching, within its brand OrganoTex, a newly developed and eco-labelled textile waterproofing with world-unique performance on the trade fair ISPO Outdoor 4-6 June in Munich. Through green chemistry that mimics nature's own water repellency, an excellent environmental profile and high technical performance are achieved. The products are biobased, biodegradable and eco-labelled and completely free of PFAS, fossil plastics, and synthetic waxes. The technology is based on combining the natural fatty acids of plants and the surface structure of leaves with the Nobel Prize-winning chemistry organocatalysis. The inspiration is the lotus leaf with its 3D structure and extreme water repellency. To succeed in this, the patented OrganoClick technology is used to "click" the natural fatty acids on the textile fibers. The result is a new generation of OrganoTex products that have improved water repellency and withstand morewashing cycles. The products are biobase and biodegradable, and contain neither PFAS, fossil-based plastics nor synthetic waxes. First out are the products OrganoTex Wash-In Textile Waterproofing and OrganoTex Spray-On Textile Waterproofing. Thanks to their excellent environmental profile, they have received the environmental label Oeko-Tex Eco Passport and USDA BioPreferred Certified Biobased Product. The products are also verified to be readily biodegradable according to the high requirements of the OECD 301F test. A world-unique product that both combines high performance and at the same time is biobased, plastic-free and biodegradable and, of course, PFAS-free. This innovation is fully in line with OrganoClick's overall mission to accelerate the phasing out of plastics and fossil chemicals towards overall vision of a nature free of plastics and toxic chemicals. Tillkännagivande • May 19
Organoclick AB (Publ) Announces Board Changes OrganoClick AB (publ) at its Annual General Meeting on 17 May 2023 the company approved and elect Chatarina Schneider as board members. And Board also gave a big thank to the outgoing board member Claes-Göran Beckeman for his important contribution to the board and the company during his 15 years as a board member. Major Estimate Revision • May 12
Consensus estimates of losses per share improve by 25% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from kr162.1m to kr166.5m. EPS estimate increased from -kr0.16 per share to -kr0.12 per share. Chemicals industry in Sweden expected to see average net income growth of 0.2% next year. Consensus price target of kr9.00 unchanged from last update. Share price fell 17% to kr3.97 over the past week. Reported Earnings • Apr 09
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: kr0.45 loss per share (further deteriorated from kr0.34 loss in FY 2021). Revenue: kr115.0m (up 4.5% from FY 2021). Net loss: kr44.4m (loss widened 36% from FY 2021). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Apr 06
Chairman recently bought kr206k worth of stock On the 3rd of April, Jan Johansson bought around 50k shares on-market at roughly kr4.11 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jan's only on-market trade for the last 12 months. Recent Insider Transactions • Feb 27
Environmental & Sustainability Director recently bought kr120k worth of stock On the 20th of February, Mattias Bodin bought around 30k shares on-market at roughly kr4.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.7m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Feb 23
Environmental & Sustainability Director recently bought kr120k worth of stock On the 20th of February, Mattias Bodin bought around 30k shares on-market at roughly kr4.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.9m more in shares than they have sold in the last 12 months. Major Estimate Revision • Feb 22
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr179.0m to kr160.0m. Forecast losses increased from -kr0.07 to -kr0.17 per share. Chemicals industry in Sweden expected to see average net income growth of 1.4% next year. Consensus price target of kr9.00 unchanged from last update. Share price fell 4.9% to kr3.81 over the past week. Reported Earnings • Feb 17
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: kr0.45 loss per share (further deteriorated from kr0.34 loss in FY 2021). Revenue: kr115.0m (up 4.5% from FY 2021). Net loss: kr44.4m (loss widened 36% from FY 2021). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. 
